TAO Synergies (TAOX) Operating Income (2024 - 2026)
TAO Synergies' (TAOX) quarterly Operating Income came in at -$1.6 million in Q2 2026, up 48.31% on a YoY basis from -$1.1 million in Q2 2025, and down 19.08% quarter-over-quarter from -$1.3 million in Q1 2026.
Analysis
TAO Synergies (TAOX) Operating Income (2024 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Operating Income for 3 consecutive years, with -$1.6 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Operating Income rose 48.31% year-over-year to -$1.6 million; the trailing twelve-month figure through Jun 2026 stood at -$7.8 million (down 2.43% YoY), and the FY2025 full-year result was -$9.0 million, down 32.84% from the prior year.
- Operating Income retreated to -$1.6 million in Q2 2026 per TAOX's latest filing, from -$1.3 million in the prior quarter.
- Across five years, Operating Income topped out at -$1.1 million in Q1 2025 and bottomed at -$3.1 million in Q4 2025.
- Historically, Operating Income has averaged -$1.9 million across 3 years, with a median of -$1.6 million in 2024.
- The sharpest annual moves came in 2025 and 2026: Operating Income tumbled 101.42% in 2025, then soared 48.31% in 2026.
- Over 3 years, Operating Income stood at -$1.6 million in 2024, then sank by 101.42% to -$3.1 million in 2025, then surged by 50.07% to -$1.6 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$1.6 million, -$1.3 million, and -$3.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.20 Bn | 198.21 Bn | 7.24 Bn | 3.51 Bn |
| 2 | Gilead Sciences | 181.83 Bn | 178.65 Bn | 6.22 Bn | -10.39 Bn |
| 3 | Vertex Pharmaceuticals | 132.47 Bn | 124.61 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.56 Bn | 3.93 Bn | 1.29 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.40 Bn | 1.37 Bn | 493.00 Mn |
| 6 | Moderna | 54.65 Bn | 49.51 Bn | 52.00 Mn | -815.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Biogen | 31.42 Bn | 30.13 Bn | 1.96 Bn | -644.50 Mn |
| 9 | Roivant Sciences | 30.21 Bn | 30.21 Bn | 1.16 Mn | -365.99 Mn |
| 10 | TAO Synergies | 30.56 Mn | 30.56 Mn | - | -1.57 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.57 Mn |
| Mar 31, 2026 | -1.32 Mn |
| Dec 31, 2025 | -3.14 Mn |
| Sep 30, 2025 | -1.80 Mn |
| Jun 30, 2025 | -3.04 Mn |
| Mar 31, 2025 | -1.07 Mn |
| Dec 31, 2024 | -1.56 Mn |
| Sep 30, 2024 | -1.98 Mn |
| Jun 30, 2024 | -1.58 Mn |